newsNew pre-clinical research suggests a 24-hour manufacturing process that produces…
30 March 2022 | By Hannah Balfour (European Pharmaceutical Review)
New pre-clinical research suggests a 24-hour manufacturing process that produces fewer, more potent CAR T cells could be the key to both reducing production timelines and improving patient access to cell therapies.